Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dachuang Cao

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Obesity (Silver Spring, Md.)|November 4, 2025
People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide TreatmentXuan Li, Dachuang Cao, Helene Sapin, et al.
JAMA Network Open|March 26, 2026
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical TrialsRodolfo J Galindo, Kimberly A Gudzune, Michelle Look, et al.
Obesity (Silver Spring, Md.)|January 15, 2026
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNTThomas A Wadden, Maria A Oquendo, Robert F Kushner, et al.
Diabetes, Obesity & Metabolism|February 25, 2025
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweightMichelle Look, Julia P Dunn, Robert F Kushner, et al.
The Journal of Clinical Endocrinology and Metabolism|October 19, 2006
Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trialWerner F Blum, Brenda J Crowe, Charmian A Quigley, et al.
Hormone Research|February 4, 2009
Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndromeWerner F Blum, Dachuang Cao, Volker Hesse, et al.
Diabetes Care|August 21, 2025
Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2Naveed Sattar, Gema Frühbeck, Fabrizio Andreelli, et al.
Obesity (Silver Spring, Md.)|July 27, 2025
Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical TrialsEvgenia Gourgari, Gitanjali Srivastava, Aaron S Kelly, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 21, 2020
Key Strategies for Overcoming Psychological Insulin Resistance in Adults with Type 2 Diabetes: The UK Subgroup in the EMOTION StudyElemer G Balogh, Magaly Perez-Nieves, Dachuang Cao, et al.
Diabetes, Obesity & Metabolism|January 10, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trialsDomenica M Rubino, Sue D Pedersen, Lisa Connery, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Obesity (Silver Spring, Md.)|November 4, 2025
People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide TreatmentXuan Li, Dachuang Cao, Helene Sapin, et al.
JAMA Network Open|March 26, 2026
Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical TrialsRodolfo J Galindo, Kimberly A Gudzune, Michelle Look, et al.
Obesity (Silver Spring, Md.)|January 15, 2026
Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNTThomas A Wadden, Maria A Oquendo, Robert F Kushner, et al.
Diabetes, Obesity & Metabolism|February 25, 2025
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweightMichelle Look, Julia P Dunn, Robert F Kushner, et al.
The Journal of Clinical Endocrinology and Metabolism|October 19, 2006
Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two-year results of a randomized, controlled, multicenter trialWerner F Blum, Brenda J Crowe, Charmian A Quigley, et al.
Hormone Research|February 4, 2009
Height gains in response to growth hormone treatment to final height are similar in patients with SHOX deficiency and Turner syndromeWerner F Blum, Dachuang Cao, Volker Hesse, et al.
Diabetes Care|August 21, 2025
Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2Naveed Sattar, Gema Frühbeck, Fabrizio Andreelli, et al.
Obesity (Silver Spring, Md.)|July 27, 2025
Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical TrialsEvgenia Gourgari, Gitanjali Srivastava, Aaron S Kelly, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 21, 2020
Key Strategies for Overcoming Psychological Insulin Resistance in Adults with Type 2 Diabetes: The UK Subgroup in the EMOTION StudyElemer G Balogh, Magaly Perez-Nieves, Dachuang Cao, et al.
Diabetes, Obesity & Metabolism|January 10, 2025
Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trialsDomenica M Rubino, Sue D Pedersen, Lisa Connery, et al.
Pageof 5